Delivery Order SPE2DB20D3303-SPE2DB25FA2HK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $15,662.64, represents a competitively awarded contract with no set-aside designation and is scheduled for completion by July 25, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units, with a ceiling value of $6,062.94. This is a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and represents no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $11,275.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 13, 2025. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $15,256.14, represents a non-competitive set-aside contract and is scheduled for completion by August 15, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,864.37 to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. XELJANZ XR is a...
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,350.64 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price delivery order represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $8,137.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement supporting federal pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2HKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units, with a ceiling value of $1,889.64. This firm fixed-price delivery order is scheduled for completion by August 11, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a task order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs, the Defense Health Agency, and other government healthcare systems. The supply of XELJANZ XR—a brand-name pharmaceutical used in the treatment of rheumatoid arthritis and other inflammatory conditions—aligns with the company's extensive portfolio of specialty medications delivered under the broader pharmaceutical prime vendor contract.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/8/25 |